BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 28597167)

  • 1. Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy.
    Abla O; Ribeiro RC; Testi AM; Montesinos P; Creutzig U; Sung L; Di Giuseppe G; Stephens D; Feusner JH; Powell BL; Hasle H; Kaspers GJL; Dalla-Pozza L; Lassaletta A; Tallman MS; Locatelli F; Reinhardt D; Lo-Coco F; Hitzler J; Sanz MA
    Ann Hematol; 2017 Sep; 96(9):1449-1456. PubMed ID: 28597167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.
    Testa U; Lo-Coco F
    Ann Hematol; 2016 Apr; 95(5):673-80. PubMed ID: 26920716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
    Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
    Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors affecting thrombohemorrhagic early death in patients with acute promyelocytic leukemia treated with arsenic trioxide alone.
    Hou W; Zhang Y; Jin B; Cao W; Lu M; Yan L; Yang H; Tian X; Hou J; Fu J; Zhao H; Li H; Zhou J
    Blood Cells Mol Dis; 2019 Nov; 79():102351. PubMed ID: 31400712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The kinetics of white blood cell and the predictive factors of leukocytosis under oral or intravenous arsenic as the first-line treatment for acute promyelocytic leukemia.
    Wang F; Jia JS; Wang J; Zhao T; Jiang Q; Jiang H; Zhu HH
    Leuk Res; 2017 Oct; 61():84-88. PubMed ID: 28934679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial.
    Burnett AK; Grimwade D; Solomon E; Wheatley K; Goldstone AH
    Blood; 1999 Jun; 93(12):4131-43. PubMed ID: 10361110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined therapy with all-trans-retinoic acid and high-dose chemotherapy in patients with hyperleukocytic acute promyelocytic leukemia and severe visceral hemorrhage.
    Dombret H; Sutton L; Duarte M; Daniel MT; Leblond V; Castaigne S; Degos L
    Leukemia; 1992 Dec; 6(12):1237-42. PubMed ID: 1453767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy.
    Lou Y; Suo S; Tong H; Ye X; Wang Y; Chen Z; Qian W; Meng H; Mai W; Huang J; Tong Y; Jin J
    Leuk Res; 2013 Nov; 37(11):1451-6. PubMed ID: 23958062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy.
    Ferrara F; Morabito F; Martino B; Specchia G; Liso V; Nobile F; Boccuni P; Di Noto R; Pane F; Annunziata M; Schiavone EM; De Simone M; Guglielmi C; Del Vecchio L; Lo Coco F
    J Clin Oncol; 2000 Mar; 18(6):1295-300. PubMed ID: 10715300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. All-trans retinoic acid therapy in relapsed/refractory or newly diagnosed acute promyelocytic leukemia (APL) in Japan.
    Ohno R; Ohnishi K; Takeshita A; Tanimoto M; Murakami H; Kanamaru A; Asou N; Kobayashi T; Kuriyama K; Ohmoto E
    Leukemia; 1994; 8 Suppl 3():S64-9. PubMed ID: 7808028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene mutations in acute promyelocytic leukemia early death in patients treated with arsenic trioxide alone.
    Chen X; Fan S; Zhao Y; Zhou J
    Clin Transl Oncol; 2021 Oct; 23(10):2171-2180. PubMed ID: 33942222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical impact of galectin-3 in newly diagnosed t (15;17)(q22;q21)/PML-RARa acute promyelocytic leukemia treated with all-trans retinoic acid and arsenic trioxide-based regimens.
    Gao N; Wang XX; Sun JR; Yu WZ; Li XZ
    Ann Hematol; 2017 May; 96(5):711-718. PubMed ID: 28238096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience.
    Kelaidi C; Chevret S; De Botton S; Raffoux E; Guerci A; Thomas X; Pigneux A; Lamy T; Rigal-Huguet F; Meyer-Monard S; Chevallier P; Maloisel F; Deconinck E; Ferrant A; Fegueux N; Ifrah N; Sanz M; Dombret H; Fenaux P; Adès L
    J Clin Oncol; 2009 Jun; 27(16):2668-76. PubMed ID: 19414681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.
    Lucena-Araujo AR; Kim HT; Jacomo RH; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Chauffaille Mde L; Chiattone CS; Lima AS; Ruiz-Argüelles G; Undurraga MS; Martinez L; Kwaan HC; Gallagher R; Niemeyer CM; Schrier SL; Tallman MS; Grimwade D; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Sanz MA; Rego EM
    Ann Hematol; 2014 Dec; 93(12):2001-10. PubMed ID: 24981688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic results with apl 93 protocol in acute promyelocytic leukemia (34 cases)].
    Jeddi R; Hdiji S; Kacem K; Ben Lakhal R; Aissaoui L; Ben Abid H; Belhadj Ali Z; Meddeb B
    Tunis Med; 2006 Nov; 84(11):717-20. PubMed ID: 17294898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of acute promyelocytic leukemia (APL) in children and adolescents: an analysis in two consecutive trials of the European APL Group.
    Bally C; Fadlallah J; Leverger G; Bertrand Y; Robert A; Baruchel A; Guerci A; Recher C; Raffoux E; Thomas X; Leblanc T; Idres N; Cassinat B; Vey N; Chomienne C; Dombret H; Sanz M; Fenaux P; Adès L
    J Clin Oncol; 2012 May; 30(14):1641-6. PubMed ID: 22473162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute promyelocytic leukemia. New methods in diagnosis and treatment.
    Varghese L; Janckila A; Yam LT
    J Ky Med Assoc; 1999 Feb; 97(2):61-5. PubMed ID: 10073058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term treatment for adult hypergranular and microgranular acute promyelocytic leukemia.
    Bassan R; Battista R; Viero P; d'Emilio A; Buelli M; Montaldi A; Rambaldi A; Tremul L; Dini E; Barbui T
    Leukemia; 1995 Feb; 9(2):238-43. PubMed ID: 7869758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience.
    Cheng Y; Zhang L; Wu J; Lu A; Wang B; Liu G
    Eur J Haematol; 2013 Dec; 91(6):483-9. PubMed ID: 24033687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive factors of all-trans-retinoic acid related complications during induction therapy for acute promyelocytic leukemia.
    Jeddi R; Kacem K; Ben Neji H; Mnif S; Gouider E; Aissaoui L; Ben Amor R; Ben Lakhal R; Ben Abid H; Belhadjali Z; Meddeb B
    Hematology; 2008 Jun; 13(3):142-6. PubMed ID: 18702871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.